Seebri Breezhaler

País: União Europeia

Língua: inglês

Origem: EMA (European Medicines Agency)

Ingredientes ativos:

Glycopyrronium bromide

Disponível em:

Novartis Europharm Limited

Código ATC:

R03BB06

DCI (Denominação Comum Internacional):

glycopyrronium bromide

Grupo terapêutico:

Drugs for obstructive airway diseases,

Área terapêutica:

Pulmonary Disease, Chronic Obstructive

Indicações terapêuticas:

Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Resumo do produto:

Revision: 12

Status de autorização:

Authorised

Data de autorização:

2012-09-28

Folheto informativo - Bula

32
B. PACKAGE LEAFLET
33
PACKAGE LEAFLET: INFORMATION FOR THE USER
SEEBRI BREEZHALER 44 MICROGRAMS INHALATION POWDER, HARD CAPSULES
glycopyrronium
(as glycopyrronium bromide)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Seebri Breezhaler is and what it is used for
2.
What you need to know before you use Seebri Breezhaler
3.
How to use Seebri Breezhaler
4.
Possible side effects
5.
How to store Seebri Breezhaler
6.
Contents of the pack and other information
1.
WHAT SEEBRI BREEZHALER IS AND WHAT IT IS USED FOR
WHAT SEEBRI BREEZHALER IS
This medicine contains an active substance called glycopyrronium
bromide. This belongs to a group of
medicines called bronchodilators.
WHAT SEEBRI BREEZHALER IS USED FOR
This medicine is used to make breathing easier for adult patients who
have breathing difficulties due to
a lung disease called chronic obstructive pulmonary disease (COPD).
In COPD the muscles around the airways tighten. This makes breathing
difficult. This medicine blocks
the tightening of these muscles in the lungs, making it easier for air
to get in and out of the lungs.
If you use this medicine once a day, it will help to reduce the
effects of COPD on your everyday life.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE SEEBRI BREEZHALER
DO NOT USE SEEBRI BREEZHALER
-
if you are allergic to glycopyrronium bromide or any of the other
ingredients of this medicine
(listed in section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor before using Seebri Breezhaler, if any of the
following applies

Características técnicas

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Seebri Breezhaler 44 micrograms inhalation powder, hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 63 micrograms of glycopyrronium bromide
equivalent to 50 micrograms of
glycopyrronium.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 55 micrograms of
glycopyrronium bromide equivalent to 44 micrograms of glycopyrronium.
Excipient(s) with known effect:
Each capsule contains 23.6 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
_ _
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Transparent orange capsules containing a white powder, with the
product code “GPL50” printed in
black above and the company logo (
) printed in black below a black bar.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Seebri Breezhaler is indicated as a maintenance bronchodilator
treatment to relieve symptoms in adult
patients with chronic obstructive pulmonary disease (COPD).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is the inhalation of the content of one capsule
once daily using the Seebri
Breezhaler inhaler.
Seebri Breezhaler is recommended to be administered, at the same time
of the day each day. If a dose
is missed, the next dose should be taken as soon as possible. Patients
should be instructed not to take
more than one dose in a day.
Special populations
_Elderly population _
Seebri Breezhaler can be used at the recommended dose in elderly
patients (75 years of age and older)
(see section 4.8).
_ _
_Renal impairment _
Seebri Breezhaler can be used at the recommended dose in patients with
mild to moderate renal
impairment. In patients with severe renal impairment or end-stage
renal disease requiring dialysis
Seebri Breezhaler should be used only if the expected benefit
outweighs the potential risk since the
systemic exposure to glycopyrronium may be increased in this
population (see sections 4.4 and